Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:38:36 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:AEMD - AETHLON MEDICAL INC - https://www.aethlonmedical.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AEMD - Q0.72.19·2.290.42.23+0.094.245.5866292.10  2.30  2.0863.368  2.1418:35:07Feb 0415 min RT 2¢

Recent Trades - Last 10 of 629
Time ETExPriceChangeVolume
18:35:07Q2.28620.14623
16:53:10Q2.290.151
16:47:20Q2.290.151
16:44:11Q2.200.06600
16:44:11Q2.200.06900
16:44:11Q2.190.05500
16:44:11Q2.280.141
16:22:38Q2.300.161
16:20:16Q2.310.1710
16:10:04Q2.230.091

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-04 08:01U:AEMDNews ReleaseAethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026
2025-12-05 09:15U:AEMDNews ReleaseAethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million
2025-12-02 08:01U:AEMDNews ReleaseAethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier(TM) Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs
2025-11-12 16:15U:AEMDNews ReleaseAethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update
2025-11-07 08:01U:AEMDNews ReleaseAethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025
2025-10-07 08:01U:AEMDNews ReleaseAethlon Medical's Hemopurifier(TM) shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial
2025-09-04 09:15U:AEMDNews ReleaseAethlon Medical Announces Pricing of $4.5 Million Public Offering
2025-09-03 08:01U:AEMDNews ReleaseAethlon Medical Announces Issuance of Hemopurifier(TM) Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC)
2025-08-13 16:15U:AEMDNews ReleaseAethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update
2025-08-05 08:01U:AEMDNews ReleaseAethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025
2025-07-15 08:01U:AEMDNews ReleaseAethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort
2025-06-26 16:15U:AEMDNews ReleaseAethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update
2025-06-20 08:01U:AEMDNews ReleaseAethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025
2025-06-18 08:01U:AEMDNews ReleaseAethlon Medical Treats Second Patient in Australian Hemopurifier(TM) Cancer Trial
2025-06-09 08:01U:AEMDNews ReleaseAethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes
2025-05-14 08:01U:AEMDNews ReleaseAethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier(TM) to Remove Platelet-Derived Extracellular Vesicles from Plasma
2025-03-10 08:01U:AEMDNews ReleaseAethlon Medical Publishes Preclinical Data on the Hemopurifier(TM) in Transplant Immunology Journal
2025-02-13 08:01U:AEMDNews ReleaseAethlon Medical to Present at the Emerging Growth Conference on February 19, 2025
2025-02-12 16:15U:AEMDNews ReleaseAethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update